Advanced Solid Tumor
Conditions
Keywords
PI3K inhibitor, PD-1 inhibitor, advanced solid tumor
Brief summary
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
Detailed description
The trial can be divided into two parts: dose escalation part and dose expansion part. Camrelizumab will be administrated intravenously in a predetermined fixed dose(200mgQ3w）in both parts. In dose escalation part,Linperlisib will be administrated from 40mgQD,60mgQD to 80 mgQD in sequence with the classic 3+3 design.The purposes of this part are figuring out the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,and observing the PK characteristics of Linperlisib when using combination with Camrelizumab. When finishing the dose escalation part,one combination dose of Linperlisib with Carelizumab will be selected to be studied on a wider scale of patients with advantage solid tumor in dose expansion part.Purposes of this part are further observing the PK characteristics of Linperlisib when using combination with Camrelizumab,while observing the preliminary efficacy of Linperlisib when using combination with Camrelizumab.
Interventions
DRUGLinperlisib Tablet
1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle; 2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib.
Sponsors
Shanghai YingLi Pharmaceutical Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18 years old≦age≦75 years old; * Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors； * Failure of previous standard treatment (sufficient prior treatment and no better treatment than participating in clinical research); * Qualified basic organ function and body condition; * The expected survival is greater than 3 months; * Adequate washout period.
Exclusion criteria
* Prior allergy to study drug components; * Chronic metabolic diseases that are poorly controlled by medication; * Brain metastases, infection, hemorrhage, autoimmune disease or cardiovascular disease, whichever is in active state; * Digestive tract diseases that affect absorption of studied drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLTs | At the end of Cycle 1 (each cycle is 21 days) | dose limited toxicities |
| TEAEs | from day 1after taking the investigational product till 30 days after withdrew from the study | treatment emergent adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Drug exposure | At the end of Cycle 1 (each cycle is 21 days) | Peak Plasma Concentration (Cmax) |
| PK parameters | At the end of Cycle 1 (each cycle is 21 days) | Area under the plasma concentration versus time curve (AUC).etc. |
| Effectiveness evaluation index | From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months | ORR、DOR、DCR、TTR、PFS、OS |
Contacts
Primary ContactLi Zhang, Doctor
Outcome results
None listed